Europe’s antitrust watchdog a few years ago announced it had reinterpreted an existing rule to expand its power to review and block certain M&A transactions likely to distort competition.

But that power already faces a challenge, as a big U.S. biotech company is asking Europe’s top court to prevent the authority from using it to block the company’s acquisition of a startup.